South Korea is rolling out regulatory changes to speed biosimilar development, including reforms to shorten review timelines, ease phase III trial requirements and simplify oversight of manufacturing changes. Read More
Amplia Therapeutics Ltd. has halted recruitment in its phase II Amplicity trial in advanced pancreatic cancer due to three dose-limiting toxicities related to the chemotherapy regimen, modified FOLFIRINOX (mFOLFIRINOX), which is being administered in combination with lead compound narmafotinib (AMP-945), a focal adhesion kinase inhibitor. Read More
Deep molecular advances are enabling precision medicine for the field of hematology, Wyndham Wilson said during a plenary session at the 2026 Korean Society of Hematology International Conference March 26. Read More
Total biopharma financings reached $25.14 billion in the first quarter (Q1) of 2026, nearly doubling the $13.12 billion in the Q1 2025. The early 2026 total comes in above the $13.19 billion recorded in 2023 and $13.66 billion in 2022, though it remains below the $38.27 billion during the same period in 2021 and $47.25 billion in 2024. Read More
Hematopoietic stem cell research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and inflammation, then, may hold the keys to preventing blood cancers, according to John E. Dick’s plenary session at the 2026 Korean Society of Hematology International Conference, held March 26, 2026. Read More
After nearly a year of threats and promises of a global biopharma tariff of 25% to 500%, U.S. President Donald Trump finally delivered it. In the name of national security, he imposed a 100% sector tariff on prescription drugs and their associated ingredients beginning in about four months for large manufacturers and six months for smaller companies. Read More
Biopharma and med-tech companies in Asia-Pacific raising money in public or private financings: 4DMedical, Adagene, Hangzhou Diagens, Stairmed. Read More
Clinical updates for biopharma and med tech in Asia-Pacific, including data readouts and publications: Adagene, Braveheart, Connect, Gan & Lee, Hengrui, Simcere, Takeda. Read More
Biopharma and med-tech happenings in Asia-Pacific, including deals and partnerships, and other news in brief: Adagene, Amgen, AP Biosciences, Aurinia, Axsome, Biocytogen, Daiichi Sankyo, Enodia, Everest Medicines, Frontier Medicines, Incyte, Kezar, LG Chem, Lupin, Nuvation, Shionogi, Taisho, Takeda, Tanabe, Tasly, Visufarma, Zai Lab. Read More
Regulatory snapshots for biopharma and med tech in Asia-Pacific, including global submissions and approvals, and other regulatory decisions and designations: 4DMedical, Abbisko, Eisai, GSK, Merck, SS Innovations. Read More
